

The Digital Examiner

www.prostaidcalgary.org

October 2020

Number 252



“No man has the right to be an amateur in the matter of physical training. It is a shame for a man to grow old without seeing the beauty and strength of which his body is capable.” Socrates

Contacts

Information

Phone: 403-455-1916

info@prostaidcalgary.org

Brad Sterling

President

president@prostaid.org

Dave Lunn

Past President

dlunn@shaw.ca

Support Groups

Frank Altin

Warriors

faltin@telusplanet.net

Wives, Partners & Caregivers

info@prostaidcalgary.org

Newly Diagnosed

info@prostaidcalgary.org

Mailing Address

PROSTAID Calgary

PO Box 72126

RPO Glenmore Landing

Calgary, Alberta

T2V 5H9

Phone: 403-455-1916

To subscribe to The Digital Examiner

info@prostaidcalgary.org

PROSTAID Calgary is self-funded.

[Click here to help us to continue our good work by donating on-line](#)



Next General Meeting:
Tuesday, October 13th, 2020 @ 7:30
p.m. via Zoom.
Please RSVP to be sent a meeting



Guest Speaker: Dr. Geoffrey Gotto, “Introduction to a New Treatment for Castrate Resistant Prostate Cancer Patients with No Metastases”

Dr. Gotto is a uro-oncologist specializing in the management of urologic malignancies, including prostate cancer. After graduating from the University of British Columbia and receiving the Wesbrook Scholar designation and Hamber Scholarship in Medicine. He went on to complete a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York and received his Masters of Public Health from Harvard. He is a Clinical Associate Professor in the Departments of Surgery and Oncology at the University of Calgary.

Dr. Gotto received the Canadian Urological Association scholarship for his research into health outcomes reporting and synoptic data acquisition. He was awarded Calgary’s Top 40 Under 40 award, in part for his work founding CAMP – the Clinic for Advanced and Metastatic Prostate Cancer at the Prostate Cancer Centre.

Dr. Gotto is the Principal Investigator for several clinical trials in advanced prostate cancer at the Prostate Cancer Centre. He was the only investigator for ARAMIS in Western Canada, and has extensive experience using darolutamide in nmCRPC. He is also participating in DAROL as an investigator (DAROL: **DARolutamide Observational study patients in nmCRPC patients.**)

He is a father to 4 yr old twins and an avid back-country skier and mountain biker

SIDE BAR:



Given the rising CV19 cases in Calgary again, the decision has been made to hold a General Meeting in October via Zoom. If you are interested in attending, please RSVP to this email or use

info@prostaidcalgary.org and a meeting invite will be sent a few days prior. If you need assistance in using Zoom, please contact me and we will set a time/day ahead of the meeting to work out the technology.

Watch for some more format and layout changes coming to the DE with the November issue. Time to freshen things up a bit.

The date for the Casino has been set at December 28 & 29th. VOLUNTEERS ARE NEEDED. If you are able and willing, please contact me and a form will be sent. Remember this is the major fund-raising event for PROSTAID Calgary and we encourage everyone to spread the word.

I wish everyone a healthy and fun-filled Thanksgiving. Here’s hoping the warm temperatures last through to Halloween.

Regards,

Dorothy Rodehutsors
Program Director
PROSTAID Calgary

Related Articles of Interest:

In anticipation of Dr. Gotto's presentation, here is some additional material regarding Darolutamide.

[Treatment of Nonmetastatic Castration-Resistant Prostate Cancer With Darolutamide](#)

- * Synopsis of clinical trial results for use of darolutamide versus a placebo.
- * Sept 2020, Advanced Prostate Cancer Centre of Excellence

[Summary Basis of Decision for Nubeqa—from Health Canada \(February 2020\)](#)

- The market authorization was based on quality (chemistry and manufacturing), non-clinical (pharmacology and toxicology), and clinical (pharmacology, safety, and efficacy) information submitted. Based on Health Canada's [review](#), the [benefit-harm-uncertainty](#) profile of the drug Nubeqa is favourable for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

[Darolutamide \(Nubeqa\) for Non-Metastatic Castration Resistant Prostate Cancer – Details](#)

- * Canadian Agency for Drugs & Technology in Health (CADTH)
- * CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. Learn why we are a trusted pan-Canadian source of credible health care evidence

Bayer Canada News Release— June 2020

[Non-metastatic castration resistant prostate cancer treatment NUBEQA® \(darolutamide\) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer](#)



Canada

In our YouTube Videos:

[Dr. Geoffrey Gotto - Pelvic Lymph Node Dissection in Prostate Cancer](#)

[Dr. Geoffrey Gotto: The Changing Landscape of Advanced and Metastatic Prostate Cancer](#)

[Video: Bayer Health, Germany on Darolutamide.](#)— Results of the Aramis Study

[Video: ARAMIS: Safety and Efficacy of Darolutamide in nmCRPC](#)

Articles of Interest:

[Darolutamide: Approved For Non-Metastatic Castration-Resistant Prostate Cancer](#)

- * Urology/Oncology Insights, September 2019

[Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019](#)

- * Germline testing (GT) is a central feature of prostate cancer (PCa) treatment, management, and hereditary cancer assessment.
- * In conclusion, the 2019 Consensus Conference created the first multidisciplinary PCa genetic implementation framework tailored to the precision medicine era. The framework, which importantly had input from NCCN panel leaders, provides guidance to a spectrum of providers to facilitate timely and responsible PCa GT for the benefit of men and their families.
- * Journal of American Society of Clinical Oncology

[Therapies for Prostate Cancer Impact Quality of Life Significantly](#)

- * After treatment, significant many men struggle with incontinence and sexual problems.
- * EAU Conference July 2020, Netherlands

[A Switch in Activation/Deactivation of the AZIN1 Gene Linked to Metastasis of Prostate Cancer](#)

- * High-risk disease that metastasized was associated with many more copies of this gene
- * EAU Conference July 2020, Netherlands

[Prostate Cancer Active Surveillance Webinar Series - Game Changing Observations to Men Considering Active Surveillance](#) (August 2020)

- * [first in a series](#) of four webinars on active surveillance (AS).
- * You can hear the whole presentation, download his slides, and sign up for the remaining 3 webinars this year [here](#)

[Types of Prostate Cancer Most Overlooked by Multiparametric Magnetic Resonance Imaging \(MRI\) August 2020](#)

- * This study characterized cancers that are systematically overlooked by mpMRI from the PROMIS study.
- * The authors conclude that prostate cancer undetected by mpMRI is lower in grade and size than visible disease. These findings reinforce the key role that mpMRI plays in risk stratification of men with suspected prostate cancer.

[Focal Therapy for Prostate Cancer: Use and Misuse of Focal Therapy](#)

- * The Society of Urologic Oncology (SUO) held a virtual meeting July 2020
- * In the session on prostate cancer, Laurence Klotz, MD, FRCSC, discussed the role of focal therapy for prostate cancer, highlighting both its role (the use) and potential pitfalls (the misuses).



Videos:

[DASL-HiCAP \(ANZUP1801\): The Impact of Darolutamide on Standard Therapy for Localized Very High-risk Cancer of the Prostate - Christopher Sweeney](#)

- * This video describes a phase 3, 1100 patient study lead by the ANZUP group which randomizes men with high-risk prostate cancer to darolutamide or standard of care.
- * July 2020, includes transcript

[Implementation of Germline Testing for Prostate Cancer](#)

- * This video discusses consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP (Poly (ADP-ribose) polymerase)inhibitors.
- * July 2020, includes transcript

[Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer](#)

- * The panel, in this video, talk about the final overall survival analysis of the PROSPER study in nonmetastatic castration-resistant prostate cancer
- * July 2020, includes transcript



New in Our Library

Look for all the new material on the library table at our next in-person meeting. The resources are physically located at the Kerby Centre and not accessible at this time.

If you require assistance in locating online resources, please contact us and someone will be happy to help.

Our YouTube Channel:

Did you know that all of the past presentations from General Meetings are uploaded and available to re-view on PROSTAID Calgary's YouTube Channel, like the two described on page 2?

Have a look back at some of the great information that has been shared over the last [EIGHT YEARS.](#)



PROSTAID Calgary On-Line



Thank you to our Sponsors and Community Partners

